GN.22 Research Group Signing Off

Jason Wats MD    Astressin-B, Research and latest Discoveries    

The decision to publicly assist the Human Trials Research team was not taken lightly, and everyone within our team was aware of the risks we would be undertaking by being the public face of a project that was no longer under our control.

Unfortunately all of our main concerns materialized, and the amount of public scrutiny that we have had to endure made it very clear, at least to me, why Research Groups tend to be enclosed environments. Note that this was not just limited to the comments we received within our own community, as many of them were encouraging, positive, or constructive criticism.

As we entered into the Human Trials, at least 50% of the comments we were filtering out due to their offensive or insulting nature, all aimed at our staff and ultimately putting our professional integrity in question.
The comments were not limited to our site; we have received numerous emails from colleagues pointing out multiple instances where our work was put in question. Do note that criticism has not been directed at our published data or methodologies being carried out; they all seemed to follow a very similar pattern, consisting in uncontrolled personal attacks with the sole objective to denigrate our image and professional careers.

These comments and accusations can be found across the most prominent Hair Loss thematic communities across the web, and most range from outrageous to defamatory. Today we inclusively received yet another series of comments contesting my personal academic credentials, claiming that I was inept to conduct a research due to a scarcity in scientific publications. Now as scientists, we have a certain degree of tolerance for speculation and scrutiny, this is however limited to the object of study and the process being conducted.

While I strongly agree that free speech is a fundamental Human right, I believe that it does not give anyone the right to publicly publish unsubstantiated allegations that could potentially jeopardize someone’s career without backing these claims with factual evidence. As a result, we are seeking legal advice in order to address this issue and to mitigate against published statements that have had, and continue to have, a negative impact on our staff’s professional integrity. (Including my own)

Unfortunately we have surpassed our tolerance threshold, and this has lead to a collective decision to stop updating this blog, effective immediately. We are currently holding talks in order to assess the potential future of the community, as technically it never belonged to us. Hopefully there will be an update regarding this in the near future.

Rest assured we are not abandoning Norma, it’s far more important than any of us individually, and it certainly would not make any sense at this point to retract from the outstanding progress that has been made.

To everyone who has supported us, we plan to provide an email address that you can use to inquiry about project progress. There are a couple of available options we are considering, from setting up regular project status through a newsletter, to opening an invite only Discussion Group. Whatever the solution might become, we do not intend to keep you out of the loop. Sarah will make a final post addressing this, but the plan is to open this to users who are already registered in our database who have provided valuable contributions to the community.

I would like to thank everyone who has accompanied us through this amazing journey and nourished our team though words of encouragement and constructive engagement. At the end of a long night locked in a lab/office, you were the reason why the long hours paid off.

Thank you.
Jason Wats MD

Norma Status – Clinical Trials – Green Lighted

Sarah Campeau    Astressin-B, Research and latest Discoveries    

We do realize it’s been far too long since our last update, but it’s been quite impossible to sit down and provide a retrospect on how things are progressing, and what has been happening during the last weeks.
We have been more involved in the Clinical Trials than we expected, and admittedl liked to be. The first phase of the trials have been extremely “paper-work” intensive, it has proven to be more of a logistic operation rather than a scientific Research project.

Let me thank everyone from this community for applying for the trials, out of the 120 candidates, we have selected 16 that applied through this community, everyone that has made it to the program has already been contacted. Rest assured that in case we extend the trials to areas outside of Delaware, we will let you know.
All of the legalities and authorizations are nearly in place, and things will finally kick off before the week is over. We are still not sure how we will be reporting on the progress, but hopefully the team that is leading the tests will be granted access to this blog and will be able to post regularly. Regardless of how things will move, we will keep you updated.

I have asked Jason for more help to keep the community flowing, and we truly appreciate your continuous support!

Norma Project Status – Clinical Trials

Jason Wats MD    Astressin-B, Research and latest Discoveries    

As most of you know by now, we are in the preparatory stages of assisting an external team in the Human Trials for project Norma. Unfortunately we cannot release specific dates art the moment but I can tell you that the trials are expected to start sooner than previously stated.

Would also take this opportunity to inform that the research team is looking for candidates that reside in the State of Delaware. We will be posting more information regarding the clinical program as soon as we can.

Project Norma- Human Trials

Jason Wats MD    Astressin-B, Research and latest Discoveries    

I am pleased to announce that we have reached an agreement with a private organization that has agreed to advance with the Human trials for project Norma. Unfortunately we cannot get into too much detail at this moment, but we will  be releasing more info during the next couple of weeks.

As many of you have requested, we will be posting information regarding the process itself and how to be a part of it, but there is still quite a bit ground to be conquered in the weeks ahead, particularly regarding HSS permits.

We are expecting a mid/2012 time-frame, but it’s still premature to talk about specific dates.

Would also like to state that our research group will have a passive role in the testing process, we will not be part of the team that will be conducting the tests.

Spectral F7

Sarah Campeau    Astressin-B, Research and latest Discoveries    

We gave been receiving an enormous amount of questions regarding a product called Spectral F7 that allegedly is based on Astressin-B. We would just like to state that during project Norma, Astressin-B was not tested topically, which means that we cannot prove or disprove in any way the efficiency of this treatment.

I would also like to point out that we have not received nor have we requested samples of the product for testing.

While we might have expressed our doubts regarding the efficiency of a topical treatment based on the compound, it would be premature and unprofessional to openly state that it doesn’t work.

Human Trials – Norma

Sarah Campeau    Astressin-B, Research and latest Discoveries    

As Jason pointed out in the Preliminary Report, we are currently in talks with a privately funded organization that is interested in conducting the Human Trials for project Norma. While there is still a lot of planning and details to be, we are confident that we have found a suitable partner in this endeavor.

While our research group will provide technical support, we will not be involved in the logistics of the trails.

During the upcoming month we will be posting a link with the details to get our community involved in the trials. Now, let me just demystify one thing; entering Human trials with the mindset that you are going to have contact with the compound is not a good idea. Human trials are experiments, they are not treatments. Remember, a great percentage of the dosages are placebo and/or very residual doses of the compound.

Norma Astressin-B – Preliminary Report

Jason Wats MD    Astressin-B, Research and latest Discoveries, Uncategorized    

Introduction

The findings below are still a “work in progress”, and while they do provide a very good indication of what the final report will look like, slight variations and alterations are to be expected, so please do take this into account when comparing preliminary data with the final report. The preliminary report does not explain the basic concept behind the study; it is a mare enunciation of data. To understand the purpose of “Norma” please consult previous reports on the project.

Unfortunately due to unforeseen circumstances we are currently unable to process data from Parcel C. Hopefully we will be able to resolve the pending problem in the upcoming days.

Dosage and administration information has been intentionally suppressed from the report. Materials will be detailed in the final report.

Methods

Each subject was placed in separate cages in order to avoid over population and social interactions that would affect the results. Cages were occasionally placed in close proximity in order to maintain minimum social interaction ratios. The compound was administered intravenously during specific intervals. Subject CRF levels were also manipulated in order to replicate specific conditions.

Data

Parcel A

Parcel A.A: 99% of the subjects are showing full regrowth, while 1% a significant results. Mild Gastrointestinal side effects noted, most notably diarrhea, and moderate salivation. Very mild hypersomnia was also registered.

Parcel A.B: 91% full of the subjects are showing full regrowth while are showing 8% significant regrowth and 1% of the subjects are showing moderate progress. Very mild gastrointestinal side effects noted, most notably diarrhea.

Parcel A.C: 87% full of the subjects are showing full regrowth while are showing 10% significant regrowth and 4% of the subjects are showing moderate progress. No side effects noted.

Relevant Annotations: The dosage of the compound in Parcel B is similar to the one in Parcel A.B, which we have determined as our mid-level dosage. Note that while none of the sub-parcels have standard CRF levels; every parcel has a control group with a neutral CRF expression. B.A being the highest expressing group, B.C is the lowest; even the lowest expressing CRF sub-group has significantly higher CRF levels than the neutral CG.

Parcel B.A: 19% of the subjects have showed full regrowth, 28% of the subjects are showing significant regrowth, 32% are showing moderate results, 18% minor progression, and 3% showed no signs of improvement. Moderate Gastrointestinal side effects noted, most notably diarrhea, accompanied by mild salivation and minor weight loss.

Parcel B.B: 44% full of the subjects have showed full regrowth, 34% are showing significant regrowth, 12% are showing moderate regrowth, 10% minor progression. Minor Gastrointestinal side effects noted, most notably diarrhea, accompanied by mild salivation and minor weight loss.

Parcel B.C: 52% full of the subjects have showed full regrowth, 36% of the subjects are showing significant regrowth, 12% are showing moderate regrowth. No side effects noted.

Preliminary conclusions

• It appears that lower dosages of the compound are not as effective

• Extreme dosages of the compound are not increasing its efficiency, but do seem to aggravate side effects. (data not present in any of the above parcels)

• The efficiency of the compound decreased as the CRF levels increased,

• Noted side effects ranging from minor to moderate: Gastrointestinal occurrences, most notably diarrhea, leading to dehydration and weight loss. Loss of muscular mass, salivation, and hypersomnia,

• Compensating extreme levels of CRF expression with extreme dosages of the compound aggravates the side effects and does not improve the efficiency of the compound,

• Subjects without extreme CRF levels responded at optimal efficiency levels having been administered moderate to high dosages of the compound,

• Significant interruptions of the administration of the compound resulted in further hair loss, (support data not present in this report)

• Intermittent administration of the compound resulted in a moderate decrease in its efficiency.

Considerations:

The next update on project Norma will be the actual final report. We estimate that the document will be done by the 5th of November, but I believe it is reasonable to state that the data will not look too different from the preliminary report. As stated before, the documentation will be made publicly available, and we will be more than open to provide additional information to privately funded research groups.

We have also been in contact with an organization that is interesting in proceeding with the Human Trials. There will be a post on this subject as the week progresses.

Norma – Status update

Sarah Campeau    Astressin-B, Research and latest Discoveries    

Hello everyone, we do apologize for the lack of updates recently, but we have been a bit short on staff in the last couple of weeks.
As promised, the preliminary report will be posted in 48 hours, we really appreciate your patience. Unfortunately the third Thyroid series installment is a bit late, hopefully I will get around to post it as soon as things get normalized.

Astressin-B– Important Notice/Alert

Sarah Campeau    Astressin-B, Research and latest Discoveries    

We have posted this alert before, but today we received worrying news of patients allegedly injecting themselves with topical solutions of Astressin-B.

I can’t stress enough how dangerous doing something like this is. Not only has the compound not been deemed safe, but injecting a solution that is intended to be used topically is boarder line insane. Please contact us in case you see people discussing this topic in forums or discussing groups so that we can intervene and help.

Astressin-B Research report – Norma – Parcel C

Sarah Campeau    Astressin-B, Research and latest Discoveries    

Parcel C consists in subjects that have been injected with distinct dosages of the compound. The main variable consists in the duration and consistency of the dosages. This means that the sub-groups within this parcel are helping us determine the efficiency of the compound given different dosages, and how the subjects react to an interruption of the injection cycle, the additional inconsistency of the dosages and duration of the treatment.

This Parcel has been divided in 8 sub-groups, all of which have ongoing experiments that require a constant and prolonged evaluation. Below is the fundamental data being collected on Parcel C;

• Does the compound leave any traces after the treatment has been interrupted?
• Do the side-effects cease after the treatment is interrupted?
• Do the results maintain after the interruption of the treatment? If so, how long are they maintained for.
• How do subjects react to extreme dosages of the compound
• How to the test subjects react to dosage fluctuations

One of the most common questions we keep getting is in regards to the efficiency of Astressin-B used in a treatment to treat hair loss in Androgenic Alopecia patients. While I cannot release a great deal of specifics at this moment, rest assured this is being fully contemplated, particularity in this Parcel.
Since most of the data on this particular parcel is still volatile, as it’s an ongoing experiment, we cannot release a lot of information, but we can safely publish the following preliminary data:

• So far the side effects have disappeared after the treatment has stopped on all sub-control groups.
• An unspecified percentage of subjects who had the treatment interrupted started losing hair again.
• An unspecified percentage of subjects who had the treatment interrupted did not start losing hair again
• High dosages of the compound increase significantly the noted side-effects
• High dosages of the compound did not increase the overall efficiency of the compound

I apologize for not being able to specify the subject conditions, but the purpose of these updates is to give our readers an idea of what we are doing and how the experiment is being conducted, not to provide the definite results.